Article

June 26 E-news art

Related Videos
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
1 expert in this video
Related Content
TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke
Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025
April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD
Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.
Site Logo
April 29th 2025

Advancing Patient Care: Innovations in Bladder Cancer

Sponsored by Pfizer
Pearls & Perspectives: innovation in male fertility care with Larry Lipshultz, MD, at AUA 2025
April 29th 2025

Pearls & Perspectives: Innovation in male fertility care with Larry Lipshultz, MD, at AUA 2025

Amy M. Pearlman, MD Larry Lipshultz, MD
Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.
Benign Prostatic Hyperlasia | Image Credit: © Judith - stock.adobe.com
April 28th 2025

Investigational ProVee System impresses in phase 3 trial in BPH

Benjamin P. Saylor
No device- or procedure-related serious AEs were observed through 12 months across the entire study population
ARANOTE substudy highlights benefits of darolutamide in Black men
April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
© 2025 MJH Life Sciences

All rights reserved.